- Home
- CRBG vs UTHR Comparison
CRBG vs UTHR Comparison
Compare CRBG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBG
- UTHR
- Stock Information
- Founded
- CRBG 1957
- UTHR 1996
- Country
- CRBG United States
- UTHR United States
- Employees
- CRBG N/A
- UTHR N/A
- Industry
- CRBG Life Insurance
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- CRBG Finance
- UTHR Health Care
- Exchange
- CRBG Nasdaq
- UTHR Nasdaq
- Market Cap
- CRBG 17.3B
- UTHR 14.4B
- IPO Year
- CRBG 2022
- UTHR 1999
- Fundamental
- Price
- CRBG $32.61
- UTHR $318.85
- Analyst Decision
- CRBG Buy
- UTHR Buy
- Analyst Count
- CRBG 14
- UTHR 12
- Target Price
- CRBG $37.43
- UTHR $392.00
- AVG Volume (30 Days)
- CRBG 3.5M
- UTHR 477.3K
- Earning Date
- CRBG 05-05-2025
- UTHR 04-30-2025
- Dividend Yield
- CRBG 2.94%
- UTHR N/A
- EPS Growth
- CRBG N/A
- UTHR 18.86
- EPS
- CRBG 1.17
- UTHR 25.10
- Revenue
- CRBG $16,561,000,000.00
- UTHR $2,994,100,000.00
- Revenue This Year
- CRBG $13.22
- UTHR $14.37
- Revenue Next Year
- CRBG $8.14
- UTHR $6.05
- P/E Ratio
- CRBG $27.77
- UTHR $12.70
- Revenue Growth
- CRBG N/A
- UTHR 19.84
- 52 Week Low
- CRBG $23.69
- UTHR $266.98
- 52 Week High
- CRBG $35.36
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- CRBG 59.48
- UTHR 62.38
- Support Level
- CRBG $30.72
- UTHR $311.62
- Resistance Level
- CRBG $32.90
- UTHR $320.91
- Average True Range (ATR)
- CRBG 0.72
- UTHR 7.20
- MACD
- CRBG -0.02
- UTHR 1.57
- Stochastic Oscillator
- CRBG 70.52
- UTHR 92.72
About CRBG Corebridge Financial Inc.
Corebridge Financial Inc provides retirement solutions and insurance products in the United States. It offers a broad set of products and services through five segments Individual Retirement, Group Retirement, Life Insurance, Institutional Markets businesses, Corporate and Other. The majority of its revenue derives from the Individual Retirement segment.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.